First Merchants Corp raised its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 0.6% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 5,135 shares of the medical instruments supplier’s stock after buying an additional 32 shares during the period. First Merchants Corp’s holdings in C.R. Bard were worth $1,623,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of BCR. Legacy Private Trust Co. boosted its stake in shares of C.R. Bard by 28.4% in the first quarter. Legacy Private Trust Co. now owns 1,194 shares of the medical instruments supplier’s stock worth $297,000 after buying an additional 264 shares during the last quarter. Pennsylvania Trust Co boosted its stake in C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock valued at $308,000 after buying an additional 35 shares in the last quarter. Gulf International Bank UK Ltd boosted its stake in C.R. Bard by 1.0% in the first quarter. Gulf International Bank UK Ltd now owns 23,124 shares of the medical instruments supplier’s stock valued at $5,747,000 after buying an additional 220 shares in the last quarter. Trust Co. of Oklahoma boosted its stake in C.R. Bard by 1.0% in the first quarter. Trust Co. of Oklahoma now owns 9,700 shares of the medical instruments supplier’s stock valued at $2,411,000 after buying an additional 100 shares in the last quarter. Finally, Creative Planning boosted its stake in C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares in the last quarter. 77.14% of the stock is currently owned by hedge funds and other institutional investors.
C.R. Bard, Inc. (BCR) opened at 318.20 on Friday. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $323.27. The stock has a market cap of $23.12 billion, a price-to-earnings ratio of 41.77 and a beta of 0.59. The company has a 50-day moving average of $319.58 and a 200 day moving average of $286.55.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The business had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same quarter in the previous year, the business posted $2.54 EPS. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. Equities analysts anticipate that C.R. Bard, Inc. will post $11.82 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were issued a $0.26 dividend. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 annualized dividend and a yield of 0.33%. C.R. Bard’s dividend payout ratio (DPR) is currently 13.67%.
TRADEMARK VIOLATION WARNING: “C.R. Bard, Inc. (NYSE:BCR) Shares Bought by First Merchants Corp” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.com-unik.info/2017/08/19/c-r-bard-inc-nysebcr-shares-bought-by-first-merchants-corp-updated-updated.html.
Several research firms have issued reports on BCR. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price target on the stock in a research note on Tuesday, June 13th. BMO Capital Markets cut shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price target on the stock. in a research note on Tuesday, April 25th. Morgan Stanley cut shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. BidaskClub cut shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $285.67.
In related news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.80% of the stock is currently owned by insiders.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
What are top analysts saying about C.R. Bard Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard Inc. and related companies.